Hello, everyone, and welcome to another working week. We hope the weekend was relaxing and enjoyable. Now, though, the time has come to resume that routine of meetings and deadlines. To cope, we are quaffing our mandatory cup of stimulation. Please feel free to join us. Meanwhile, here are a few items from around the world. Hope your day goes well and stay in touch...
AstraZeneca Raises Forecast After Settling Tax Dispute (Bloomberg News)
Novartis Invests In Chinese Vaccine Maker (InPharma Technologist)
Pfizer Employee Arrested For Carrying Knife On Plane (New York Post)
Speculation Rises That Roche Is A Takeover Target (Pharma Times)
Pfizer Recalls Two Drugs Over Mislabeling (MoneyControl)
Non-Profit Proposal Would Save 25 Pfizer Research Jobs (The Day)
Actelion Board Seeks Rejection Of Elliott Plan (Reuters)
How Ligand Used The Recession To Build A Pipeline (Xconomy)
China Cuts Retail Drug Prices To Curb Inflation (Reuters)
Pfizer Can Call Expert Witness In Neurontin Case (Courthouse News)
Australian Drugmakers Claim Government Is Hurting Them (The Herald Sun)
1 Comment
Re. Roche takeover, quote Roche family member:
"Roche will not be up for sale, and added that a marriage between Roche and Novartis "makes even less sense than it did five or 10 years ago," given their different strategic directions."
Applying the Jim Cramer rule, this means that a sale is imminent.